Yesterday the Michael J. Fox Foundation for Parkinson's Research hosted the second call in our ongoing Hot Topics Seminar Call Series, updating the Parkinson's community on various approaches to Parkinson's disease-modifying therapies and how biomarkers affect our ability to test these therapies.
Hosted by Michael J. Fox Foundation CEO Todd Sherer, PhD, and joined by President and Senior Scientist at the Institute for Neurodegenerative Disorders, Ken Marek, MD, the discussion touched on research projects underway in Germany and Pennsylvania, our current understanding of neurodegeneration, and addressed the challenges of testing potential therapies.
Throughout the call Drs. Marek and Sherer reminded participants of the importance of clinical trials to establish efficacy and safety of potential therapies, urging participation in clinical trials. Dr. Sherer referred the audience to Fox Trial Finder to discover clinical trials currently recruiting in their area. Those interested in trials related to biomarkers or neuroprotection research can search for trials by that criteria.
If you missed the call, catch up with the recording below and check out an archive of our chat on Twitter. Learn more about our Seminar Call Series at www.michaeljfox.org/hottopics. Join us for our next call on June 14th, “Living with PD: Going Beyond Medications.” To RSVP email email@example.com.
Hot Topics Seminar Call Series -- Disease-modifying Therapies & Biomarkers
Moderated by: Todd Sherer and Ken Marek